



Original Article

## Association between Beta-lactam Antibiotic Resistance and Virulence Factors in AmpC Producing Clinical Strains of *P. aeruginosa*

Sanaz Dehbashi <sup>a</sup>, Hamed Tahmasebi <sup>b</sup>, Mohammad Reza Arabestani <sup>a,\*</sup><sup>a</sup> Department of Microbiology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran<sup>b</sup> Department of Microbiology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

### ABSTRACT

#### Article history:

Received: July 10, 2018

Revised: October 16, 2018

Accepted: October 22, 2018

#### Keywords:

antibiotic resistance,  
beta-lactamases,  
virulence factors

**Objectives:** The purpose of this study was to determine the presence of *IMP* and *OXA* genes in clinical strains of *Pseudomonas aeruginosa* (*P. aeruginosa*) that are carriers of the *ampC* gene.

**Methods:** In this study, 105 clinical isolates of *P. aeruginosa* were collected. Antibiotic resistance patterns were determined using the disk diffusion method. The strains carrying AmpC enzymes were characterized by a combination disk method. Multiplex-PCR was used to identify resistance and virulence genes, chi-square test was used to determine the relationship between variables.

**Results:** Among 105 isolates of *P. aeruginosa*, the highest antibiotic resistance was to cefotaxime and aztreonam, and the least resistance was to colistin and ceftazidime. There were 49 isolates (46.66%) that showed an AmpC phenotype. In addition, the frequencies of the resistance genes were; *OXA48* gene 85.2%, *OXA199*, 139 3.8%, *OXA23* 3.8%, *OXA2* 66.6%, *OXA10* 3.8%, *OXA51* 85.2% and *OXA58* 3.8%. The *IMP27* gene was detected in 9 isolates (8.57%) and the *IMP3.34* was detected in 11 isolates (10.47%). Other genes detected included; *lasR* (17.1%), *lasB* (18%) and *lasA* (26.6%). There was a significant relationship between virulence factors and the *OX* and *IMP* genes ( $p \leq 0.05$ ).

**Conclusion:** The relationship between antibiotic resistance and virulence factors observed in this study could play an important role in outbreaks associated with *P. aeruginosa* infections.

<https://doi.org/10.24171/j.phrp.2018.9.6.06>  
pISSN 2210-9099 eISSN 2233-6052

©2018 Korea Centers for Disease Control and Prevention. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Beta-lactams are used globally as the appropriate choice to cure bacterial infections. These drugs inhibit cell wall construction and possess a beta-lactam central circle [1]. In the past decades, several extended spectrum beta-lactamases (ESBLs) have been discovered in gram negative bacteria and have been classified into 4 groups including; penicillinases, metallo beta-lactamases, oxacillinases and cephalosporinases. Class C has an enzyme named AmpC. All strains of *Pseudomonas aeruginosa* (*P. aeruginosa*) carry an attenuated transcript of the *ampC* gene on the chromosome which could be induced by exposure to first generation cephalosporines and produce

AmpC enzymes. Also, *P. aeruginosa* produces a wide range of beta-lactamases which are transferred on plasmids and other mobile genetic elements [2].

*IMP-1* belongs to Class B of the beta-lactamases with extended spectrum metallo beta-lactamases, which hydrolyze all beta-lactams except for aztreonam, and are resistant to clavulanic acid and sulbactam [2]. Since these enzymes hydrolyse imipenem and meropenem, they are known as carbapenemase. *IMP* was firstly reported in *P. aeruginosa* as a gene carried on plasmid, and then subsequently discovered that it could be transferred on integrons. Therefore, this may explain why *IMP* spreads in some genus of enterobacteriaceae [3]. The other group of beta-lactamases are oxacillinases.

\*Corresponding author: Mohammad Reza Arabestani  
Department of Microbiology, Faculty of Medicine, Brucellosis research center, Hamadan University of Medical Sciences, Hamadan, Iran  
E-mail: mohammad.arabestani@gmail.com

They are susceptible to clavulanic acid (except for OXA-48) and hydrolyse ceftazidime and aztreonam. Oxacillinases are carried on plasmids except for OXA-18. However, oxacillinases and their variants such as OXA-51, OXA-23 and OXA-58 are more prevalent in enterobacteriaceae, due to genetic circulation and Horizontal Gene Exchange (HGT) mechanisms observed in *P. aeruginosa* [4].

One of the clinical significances of *P. aeruginosa* is its ability to secrete several virulence factors. Many virulence factors in *P. aeruginosa* are horizontally acquired, as reflected by the great diversity within the species. In addition, it is noteworthy that virulence factors are likely to perform a useful function for any organism within their natural environment, and that as *P. aeruginosa* is not an obligate parasite of humans, many factors harmful to humans expressed by this organism will most probably perform a more innocuous function within the organism's natural habitat [5]. Quorum Sensing (QS) and biofilm formation are one of the most important virulence factors of this bacterium and several systems have been characterized, such as those from *Vibrio fischeri*, *P. aeruginosa*, and *Staphylococcus aureus*. *P. aeruginosa* utilizes two AHL (Acyl Homoserine Lactone) based QS systems; Las, Rhl, a non AHL mechanism and the Pseudomonas Quinolone Signal (PQS) system [6].

Among antibiotic resistant strains of *P. aeruginosa*, enhanced biofilm production and a coordinating regulatory protein to switch on and off antibiotic resistance have been observed [7]. Elastase (syn: pulmonary elastase, *LasB*) is the most powerful proteolytic enzyme secreted by *P. aeruginosa*, accounting for 90% of its proteolytic activity. Elastase is coded by *lasB*, the expression of which is controlled through the las QS pathway, and is produced in greatest quantity when cells are in the late logarithmic phase of growth or at high cell density [5,6]. *P. aeruginosa* also produces a second elastolytic enzyme, the serine protease LasA (coded by *lasA*). This enzyme was thought to nick elastin, exposing active sites for proteolysis by *LasB*. Subsequent studies have however shown that the enzyme is capable of elastolytic activity independent of *LasB* and *Apr* [6].

From another point of view, AmpC producing *P. aeruginosa* could have intrinsic non-induced resistance against some antibiotics. Although uridopenicillins and third generation cephalosporines are unstable against AmpC, they do not induce AmpC synthesis [8]. Therefore, these antibiotics are active unless AmpC is induced, however, spontaneous mutants would be produced by intermediate frequency. Therefore, the aim of this study was to determine the association between beta-lactam antibiotic resistance and virulence factors in AmpC producing *P. aeruginosa*.

## Materials and Methods

### 1. Collection of specimens

In this descriptive-analytic study, which was performed in a period of 7 months from May 2015 to April 2016, different clinical specimens were collected including blood, urine, cerebrospinal fluid, ulcer secretions, chip, burn wounds, catheters, and others, from the educational hospitals affiliated to Hamadan University of Medical Science. The criteria for entering individuals for sampling were patients who were hospitalized for a long time and suspected of bacterial infection. Collected samples were immediately placed in nutrient broth and transferred to the laboratory of the Microbiology Department, Faculty of Medicine, Hamadan University, Iran. This study was supported by the Vice-Chancellor for Research at Hamadan University of Medical Sciences (Grant No.: 9510075755) and was approved by the Ethics Committee of Hamadan University of Medical Sciences (Code No.: IR.UMSHA.REC.1395402).

### 2. Isolation and identification of *P. aeruginosa*

The isolates were cultured on blood agar and MacConkey agar (Merck, Germany) and incubated at 42°C. *P. aeruginosa* showed a lactose non-fermenter appearance on MacConkey agar. The resulting colony was then transferred to the TSI (Merck, Germany). The isolates were all oxidative organisms when grown on Hugh and Liefson medium and were able to reduce nitrate to nitrite. Identification of tested isolates was confirmed with an API 20E (bioMérieux) identification kit. Stock cultures were stored in 0.05 M K-Na-phosphate buffer, pH 7.0, and containing 15% glycerol at -20°C.

### 3. Minimum inhibitory concentration testing

All tested *P. aeruginosa* isolates were screened for minimum inhibitory concentration (MIC) testing to 10 different antimicrobials, Cefoxitin, Ceftazidime, Cefotaxime, Aztreonam, Ceftriaxone, Colistin, Meropenem, Doripenem, Ertapenem, and Imipenem using E- test strips (Liofilchem, Italy) on Mueller-Hinton agar media following the zone diameter criteria recommended by the Clinical and Laboratory Standards Institute. For the purpose of analysis, isolates with resistant phenotypes and also those classified as having intermediate resistance were included [9,10].

### 4. AmpC testing

Based on Clinical and Laboratory Standards Institute recommendations, to investigate AmpC producing strains of *P. aeruginosa*, cefoxitin (30µg) disks (Mast. England) were used with AmpC inhibitors based on the study by Tam et al [3].

*Klebsiella pneumoniae* ATCC700603 and *P. aeruginosa* ATCC27853 were applied as positive and negative control, respectively [9-11].

## 5. Genomic DNA and plasmid extraction

Strains were inoculated in LB broth (Merck, Germany) and incubated at 37°C. In order to extract genomic DNA and plasmid, an extraction kit (Qiagen, Germany) was used according to the manufacturer's instructions.

## 6. PCR Amplification and Gel Electrophoresis

For the amplification of resistance and virulence genes, sequences of primers proposed by Mlynarcik et al [11] and Fazeli et al [12] were used. The programmable thermal cycler (Eppendorf, Mastercycler® 5332, Germany) device was used in all PCR reactions. The first- third multiplex PCR reaction was used for the detection of betalactamas genes and fifth reaction was used for the detection of virulence genes of *P. aeruginosa* isolated from clinical samples. The PCR reaction was performed in a total volume of 50 µL, containing 1 µL of DNA template, 2 mM MgCl<sub>2</sub>, 250 µM dNTP (Fermentas, Waltham, Massachusetts, United States), 1 µM of each primer, 1.25 U Taq DNA polymerase (Fermentas, Fermentas, Waltham, Massachusetts, United States), and 5 µL PCR buffer 10X. The DNA was amplified using the following protocol: initial denaturation (94°C for 5 min), followed by 35 cycles of denaturation (94°C for 45 seconds), annealing and extension (72°C, from 1 min), with a single final extension of 5 min at 72°C. PCR products were separated in 1% agarose gel for 65 min at 85 volts, stained with Gel Red 3X (Biotium, Fremont, CA) and detected by UV transilluminator.

## 7. Sequencing

PCR products (amplicons) were purified and sequenced by Bioneer Co., Korea mediated by Pishgam Co., Iran and the data were analyzed using the Chromas software and compared to the microbial genome using the Basic Local Alignment Search Tool (BLAST) in order to confirm the sequence authenticity.

## 8. Statistical analysis

Statistical presentation and analysis of the present study was conducted, using the mean, standard error, chi-square and linear correlation coefficient tests of SPSS 16.0 for Windows (SPSS, Inc. Chicago, IL, USA).

## Results

Out of 105 *P. aeruginosa* clinical isolates, 79 isolates (75.23%) were collected from women and 26 isolates (24.76%) from men,

most of whom were between 20-40 years old. From the 105 clinical isolates, 55 isolates (48.57%) were obtained from burn wounds, 24 isolates (22.85%) from blood cultures, 14 isolates (13.33%) from urine, 9 isolates (15.78%) from catheters, and 3 isolates (2.85%) from discharges.

### 1. MIC and AmpC producer strains of *P. aeruginosa*

An antibiotic resistance pattern and MIC test for various antibiotics are shown in Table 1. Based on these results, 74 isolates (70.74%) were resistant to cefotaxim, 19 isolates (18.09%) resistant to azteronam, 91 isolates (86.66%) resistant to ceftriaxone, 2 isolates (1.94%) resistant to ceftazidime, 49 isolates (46.66 %) resistant to cefoxitin, and 1 isolate with intermediate resistance to colistin. Out of 48 AmpC producer strains, 39 isolates (81.2%) were resistant to cefotaxime, 16 isolates (33.33%) resistant to azteronam, 44 isolates (91.6%) resistant to ceftriaxone, 2 isolates (4.16%) resistant to ceftazidime, and 46 (96%) resistant to cefoxotin were observed. Out of 105 isolates, 48 isolates (54.71%) were AmpC producing *P. aeruginosa* which were collected from burn wounds (21 isolates), blood (11 isolates), urine (9 isolates), and catheters (7 isolates). Patients colonized with AmpC producer strains were between 40-60 years old.

### 2. Frequency of resistance genes in AmpC and non-AmpC producer strains

Out of the 48 isolates that carried the AmpC encoding gene, 3 isolates (6.25%) were positive for OXA-48, 4 isolates (8.33%) positive for OXA-199,139, 4 isolates (8.33%) positive for OXA-23, 7 isolates (14.58%) positive for OXA- 2, 4 isolates (8.33%) were OXA- 10 producers, 3 isolates (6.25%) were OXA-51 producers, and 4 isolates (8.33%) positive for OXA-58 were observed. *IMP3*, *34* and *IMPexpt-3*, *16*, *31*, *35* were detected in 11 isolates (11%) and 10 isolates (20.83%), respectively (Tables 2, 3; Figure 1).

### 3. Relationship between Variants

There was a significant correlation between antibiotic resistance and virulence factors (Tables 4 and 5). In addition, there was a significant relationship between the presence of AmpC enzymes and OXA and IMP genes. AmpC producing *P. aeruginosa* strains were significantly associated with resistance to cefoxitin, cefpodoxime, cefotaxime, ceftazidime, ciprofloxacin, colistin, azteronam, and ceftriaxone ( $p < 0.05$ ), as determined using SPSS16 software.

### 4. Results of gene sequencing

All our PCR products were assigned to the microbial genome using the Basic Local Alignment Search Tool (BLAST) and showed the same DNA sequences, therefore all PCR assay results were confirmed.

Table 1. MIC antimicrobial resistance pattern in clinical isolates of *P. aeruginosa* with or non.

Agent	No. of isolates with indicated MIC values (mg/L)											Indicated susceptibility (%)															
	≤ 0.5	1	2	4	8	16	32	64	128	≥ 256	≤ 0.5	1	2	4	8	16	32	64	128	≥ 256	AmpC n = 48			non-AmpC n = 57			
	AmpC n = 48											non-AmpC n = 57											S (%)	I (%)	R (%)	S (%)	I (%)
FOX	2	0	0	0	0	0	0	10	19	17	25	7	22	0	0	0	3	0	0	0	2 (4)	0	46 (96%)	54 (95)	0	3 (5)	
CAZ	20	18	3	0	5	0	2	0	0	0	20	4	19	2	0	0	0	0	0	0	41 (86)	5 (10)	2 (4%)	57 (100)	0	0	
CTX	8	0	1	0	0	0	4	14	5	17	2	12	3	5	0	0	0	24	2	9	9 (19)	0	39 (81%)	22 (39)	0	35 (61)	
ATM	6	0	5	7	19	0	2	7	0	7	49	11	1	0	0	0	2	1	0	0	32 (67)	0	16 (33%)	54 (95)	0	3 (5)	
CRO	4	0	0	0	0	0	0	3	22	19	5	5	0	0	0	0	32	17	0	0	4 (9)	0	44 (91%)	10 (18)	0	47 (82)	
CL	29	11	6	2	0	0	0	0	0	0	33	59	0	0	0	0	0	0	0	0	46 (96)	2 (4)	0	57 (100)	0	0	
MER	17	22	0	0	8	1	0	0	0	0	72	18	0	0	0	0	0	0	0	0	39 (81)	8 (16)	1 (3%)	57 (100)	0	0	
DOR	12	9	24	3	0	0	0	0	0	0	57	0	0	0	0	0	0	0	0	0	45 (94)	3 (6)	0	57 (100)	0	0	
ETP	36	10	0	0	2	0	0	0	0	0	43	14	0	0	0	0	0	0	0	0	46 (96)	2 (4)	0	57 (100)	0	0	
IMI	27	15	3	3	0	0	0	0	0	0	22	63	0	0	0	0	0	0	0	0	45 (94)	3 (6)	0	57 (100)	0	0	

ATM = Aztreonam; CAZ = Ceftazidime; CL = Colistin; CRO = Ceftriaxone; CTX = Cefotaxime; DOR = Doripenem; ERP = Ertapenem; FOX = Cefoxitin; IMI = Imipenem; I = intermediate; MER = Meropenem; R = resistant; S = susceptible.

Table 2. Distribution of antimicrobial resistance and virulence factors genes in clinical isolates of *P. aeruginosa* AmpC.

Source of Isolation	Ampc Strain	blaOXA-48	blaOXA-51	blaOXA-23	blaOXA-27	blaOXA-10	blaOXA-2	blaOXA-58	blaOXA-199	bla <sub>IMP(3,34)</sub>	bla <sub>IMP-27</sub>	bla <sub>IMP</sub> variants	lasA	laB	lasR
Burn Wound infection	33	2	1	2	3	3	1	4	0	4	1	4	4	6	3
Female	24	2	1	1	3	2	1	3	0	2	2	1	3	1	0
Male	9	0	0	1	0	2	0	1	0	2	0	4	1	5	3
Urine Culture	9	1	1	1	3	0	5	0	3	5	0	0	1	1	2
Female	8	1	1	0	2	0	4	0	2	5	0	0	1	1	1
Male	1	0	0	0	1	0	1	0	1	0	0	0	0	0	1
Discharge infection	1	0	0	1	2	0	0	0	1	0	0	0	0	0	0
Female	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Male	1	0	0	0	2	0	0	0	1	1	0	0	0	0	0
Catheter infection	5	0	0	0	0	0	0	0	0	1	0	0	3	7	5
Female	1	0	0	0	0	0	0	0	0	0	0	0	3	5	4
Male	4	0	0	0	0	0	0	0	0	1	0	0	0	2	1
Blood Culture	10	0	1	0	1	0	0	0	0	1	0	0	0	0	0
Female	7	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Male	3	0	1	0	0	0	0	0	0	1	0	0	0	0	0
Total	48	3	3	4	9	4	7	4	4	11	2	4	8	14	12
Female	32	2	2	3	6	2	5	3	2	8	2	1	7	7	5
Male	16	1	1	0	3	2	2	1	2	3	0	3	1	7	6

## Discussion

The relationship between antibiotic resistance patterns and the presence of virulence factors has been widely studied. Other factors may influence the activity of virulence factors in *P. aeruginosa*, including gender, type of clinical specimen, and even the activity of certain antibiotic resistance enzymes [12,13]. In this study, the highest frequency of virulence strains was isolated from female patients. The role of gender in the exacerbation of infections caused by *P. aeruginosa* were examined in this study. As previously mentioned in different studies from Iran, Canada and United States, the severity of infection may be affected by gender [14,15]. In accordance with studies in Iran, Pakistan, Sudan, Italy, and China, our data demonstrated high resistance to ceftriaxone and cefotaxime, and highest susceptibility to carbapenems. It seems that selection pressure occurs when there is exposure to microorganisms due to increased consumption of cephalosporin in healthcare settings and the community,




Figure 1. Results of *IMP* and *OXA* genes. (A) *OXA-23* (736bp), *IMP-27* (169 bp), *OXA-10* (453bp) and *OXA-2* (568 bp). Third well: Positive control, sixth well: Negative control. (B) *OXA-19, 37* (597 bp), *OXA-51* (435 bp), *IMP* (183 bp). Second well: positive control, First well: negative control. (C) *OXA-58* (740 bp), *IMP-31* (523 bp), Column 2: positive control, column 1: negative control.

Table 3. Distribution of antimicrobial resistance and virulence factors genes in clinical isolates of *P. aeruginosa* with non-AmpC.

Source of Isolation	Non-AmpC Strain	<i>blaOXA-48</i>	<i>blaOXA-51</i>	<i>blaOXA-23</i>	<i>blaOXA-27</i>	<i>blaOXA-10</i>	<i>blaOXA-2</i>	<i>blaOXA-58</i>	<i>blaOXA-48</i>	<i>bla</i> <small>(IMP(3, 34))</small>	<i>bla</i> <small>(IMP-27)</small>	<i>bla</i> <small>IMP variants</small>	<i>lasA</i>	<i>laB</i>	<i>lasR</i>
Burn Wound infection	0	0	0	0	0	0	0	0	0	4	1	1	11	3	2
Female	0	0	0	0	0	0	0	0	0	1	1	1	8	2	1
Male	0	0	0	0	0	0	0	0	0	3	0	0	3	1	1
Urine Culture	0	0	0	0	0	0	0	0	0	1	1	2	8	2	2
Female	0	0	0	0	0	0	0	0	0	1	1	2	4	0	1
Male	0	0	0	0	0	0	0	0	0	0	0	0	4	2	1
Discharge infection	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Catheter infection	0	0	0	0	0	0	0	0	0	1	0	0	2	0	2
Female	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2
Male	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Blood Culture	0	0	0	0	0	0	0	0	0	5	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	4	0	0	0	0	0
Male	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Total	0	0	0	0	0	0	0	0	0	9	0	0	20	5	6
Female	0	0	0	0	0	0	0	0	0	4	0	0	12	3	5
Male	0	0	0	0	0	0	0	0	0	5	0	0	8	2	1

Table 4. Analysis of variables significantly associated with virulence factors, *P. aeruginosa* with antimicrobial resistance and *P. aeruginosa* without antimicrobial resistance.

Variable	Level	<i>P. aeruginosa</i> with antimicrobial resistance	<i>P. aeruginosa</i> without antimicrobial resistance	<i>p</i>
Presence of virulence genes				
Presence of <i>lasR</i>	0*	2	18	0.012
	1*	16	12	
Presence of <i>lasB</i>	0	4	25	0.006
	1	14	5	
Presence of <i>lasA</i>	0	7	23	0.045
	1	11	7	

\*0 indicated not present, and 1 indicated present.

Table 5. Analysis of variables significantly associated beta-lactamase resistance, virulence factor genes and AmpC- *P. aeruginosa* and non-AmpC- *P. aeruginosa*.

Variable	Level	AmpC- <i>P. aeruginosa</i>	non-AmpC- <i>P. aeruginosa</i>	<i>p</i>
Presence of Antibiotic Resistance and Virulence Factors genes				
Presence of <i>blaOX-2</i>	0*	41	57	0.001
	1*	7	0	
Presence of <i>blaOX-10</i>	0	44	57	0.006
	1	4	0	
Presence of <i>blaOX-23</i>	0	44	57	0.006
	1	4	0	
Presence of <i>blaOX-27</i>	0	39	57	0.008
	1	9	0	
Presence of <i>blaOX-48</i>	0	41	57	0.001
	1	7	0	
Presence of <i>blaOX-51</i>	0	41	57	0.001
	1	7	0	
Presence of <i>blaOX-58</i>	0	44	57	0.006
	1	4	0	
Presence of <i>blaOX-199</i>	0	44	57	0.006
	1	4	0	
Presence of <i>blaIMP-3,34</i>	0	37	52	0.04
	1	11	5	
Presence of <i>blaIMP-27</i>	0	44	57	0.006
	1	4	0	
Presence of <i>blaIMP-var</i>	0	42	53	0.45
	1	6	4	
Presence of <i>lasR</i>	0	36	51	0.05
	1	12	6	
Presence of <i>lasB</i>	0	34	52	0.006
	1	14	5	
Presence of <i>lasA</i>	0	40	37	0.04
	1	8	20	

\*0 indicated not present, and 1 indicated present.

resulting in enhanced resistance [16-19].

Four isolates in our study were found to harbor both *lasA* and *lasB*, with 5 isolates carrying the *lasR* gene. These isolates included 4 isolates from the same patient. Therefore, previous assertions that these genes are mutually exclusive in clinical isolates were contradicted in this study, as also noted in a number of previous studies [12]. The frequency of pathogenic genes in our study differs from the results showing *lasA*, *lasB* and *lasR* genes being present in a clinical specimen, but the effect of these genes on the abundance of each other has also been previously shown [11,12,14].

One of the main reasons for the increased activity of *P. aeruginosa* in women may be the imbalances in the body's hormonal system. Estrogen intensifies inflammation due to increases in neutrophils and other white blood cells which results in an elevated level of biofilm formation in *P. aeruginosa* strains and consequently antibiotic resistance [13]. Menstruation in women causes iron deficiency in the body. *P. aeruginosa* uses 2 siderophores for transferring trivalent iron. In the studies by Oglesby et al [13] and Tomaras et al [15], the effects of presence and absence of iron in the body of the patients were investigated, showing a significant relationship between the presence of iron and antibiotic resistance in *P. aeruginosa*. It was also reported that the bacterium was detected in the presence of iron and could increase its pathogenic activity. Although, the prevalence of infections in males was reported to be higher than females in some studies from Canada and Belgium [20,21].

Variables such as antibiotic resistance, temperature variations, gene mutations, changes in the position of genes from chromosomal to plasmid, and the presence of certain elements can affect the appearance of virulence factors [15]. In our study, there was a significant relationship between antibiotic resistance and virulence factors. In a study by Schroeder et al [7], one of the bacterial resistance factors was antibiotic alteration of external structure and the production of certain specific proteins. In this way, the bacteria, when exposed to high concentrations of antibiotics, also changed the activity of their regulatory systems due to their adaptation, which produced biofilms and initiated QS activity. QS activates 2 component systems, and this triggers the occurrence of high levels of resistance in the bacteria [7].

Meanwhile, virulence factors can affect some beta-lactamase enzymes. The study on AmpC type beta-lactamase began in the late 1970s. AmpC enzymes, which are often inducible by beta-lactams, are coded by chromosomal genes and are also found in many strains of *P. aeruginosa* [22]. Extended resistance to a wide range of antibiotics and even carbapenems may be developed in AmpC producer strains of *P. aeruginosa*. In the current study, more than half of isolates were AmpC producers with a high prevalence of resistance to cefoxitin and

ciprofloxacin. Many studies in Malaysia, USA, Saudi Arabia and Iran, have demonstrated that induced phenotype of cefoxitin and ciprofloxacin in AmpC producing *P. aeruginosa* was more frequent than for other antibiotics. Antibiotic resistance patterns for *P. aeruginosa* strains could be influenced by various factors including gender, age and place of residence, so that, in this study, 72.23% of isolates were collected from females. This difference might be due to hormone levels in women affecting mutation of regulators of Class C amblor classification. As age increases, immune systems may become dysfunctional, that may lead to resistance to different antibiotics [11].

In the current study, a meaningful relationship between strains expressing IMP and OXA genes and AmpC producer strains is observed, however, IMP and OXA genes were not frequently detected. In a study from Taiwan in 2005, OXA- type ESBLs were reported in 3.5% of cases, and the most prevalent type was OXA-17 [23]. Furthermore, in a number of studies performed to examine OXA gene prevalence, less than 10% of ESBLs producer strains in *P. aeruginosa* were shown to be of the OXA type [24-26]. Serine functions in the active site of beta-lactamases leads to changes in AmpC strains. In other words, AmpC mutated regulators could affect other resistance groups. Furthermore, function of these strains causes emergence of multidrug resistant strains. To illustrate, subtypes of OXA gene clusters like OXA-162, have been isolated from AmpC producer strains. As described by Rafiee et al [27] *P. aeruginosa* AmpC producers show 11.9% ESBLs, with MBLs produced simultaneously.

AmpC activity in gram negative bacteria results in resistance to carbapenems. In this study, antibiotic resistance patterns demonstrated that AmpC could influence genotypic and phenotypic resistance patterns in a manner that may lead to increased IMP gene activity. All IMP genes were detected in AmpC producing *P. aeruginosa*. Although some studies mention no relationship between genotypic and phenotypic resistance in AmpC producer strains, there was no evidence for this in the current study [28].

The present study showed that there was a significant relationship between the presence of beta-lactamase genes and AmpC enzymes. The genes responsible for the resistance of  $\beta$ -lactamase-resistant enzymes, such as AmpC and ESBLs, are in some cases transported onto the plasmid. This causes the transfer of genes between different gram-negative bacteria and causes the creation of resistant and pathogenic strains. In a study by Logan et al [29], genes located on plasmid were shown to be one of the most important reasons for the development of Enterobacteriaceae via the enzyme AmpC and ESBLs. However, ESBLs and AmpC can confer carbapenem resistance when associated with alteration or loss of porins, a family of proteins on the outer membrane of gram-negative bacteria [30].

The results of this study showed that the genes responsible

for resistance to various antibiotics were more frequent in isolates with a high pathogenicity. However, the prevalence of these isolates was highest in burn wounds and urine specimens. The presence of strains with QS element genes in burn wounds and urinary tract infections was due to the fact that bacteria increase their biofilm production and can resist external and environmental factors. As mentioned in studies by Heydari et al [31], Turk [32] and Ellappan et al [33] biofilm producer strains of *P. aeruginosa* indicated a high level resistance to ESBLs, MBLs and carbapenemases. In other words, *P. aeruginosa* has a high resistance to many antimicrobial and antiseptic agents. In addition, the widespread use of antibiotics in recent years has made the bacterium resistant to broad-spectrum antibiotics from various antibiotic groups.

The results of this study showed that the samples obtained from burn and discharge wounds had the highest genetic distribution. Also, infections caused by catheter and urinary tract infections also had a remarkable distribution for *ampC* genes. Cornut et al [34] showed that samples that have been exposed to infections caused by high levels of antibiotics, are more resistant to antibiotics and treatment than other bacterial infections. Thus, this relationship indicates that the detection of strains carrying the enzyme AmpC can be prevented. Therefore, it is suggested that in subsequent studies, the measurement of the level of elastase (*lasB*) and serine protease (*lasA*) enzymes should be measured.

## Conclusion

The association between antibiotic resistance and virulence factors may play a significant role in outbreaks of *P. aeruginosa* infections. Therefore, the presence of virulence factors in *P. aeruginosa* may cause some changes in beta-lactam resistance, so that QS and biofilm provide a basis for resistance to beta-lactamase enzymes. In addition, the activity and presence of certain enzymes such as elastase (*lasB*) and serine protease (*lasA*) in strains with resistance should be considered.

## Conflicts of Interest

No potential conflicts of interest relevant to this article.

## Acknowledgments

The authors of this article are grateful to Hamadan University of Medical Sciences for their financial support in conducting research.

## References

- [1] Voulgari E, Poulou A, Dimitroulia E, et al. Emergence of OXA-162 Carbapenemase- and DHA-1 AmpC Cephalosporinase-Producing Sequence Type 11 Klebsiella pneumoniae Causing Community-Onset Infection in Greece. *Antimicrob Agents Chemother* 2016;60(3):1852-54.
- [2] Easwaran S, Yerat R, Ramaswamy R. A study on detection of extended-spectrum beta-lactamases (ESBLs) and comparison of various phenotypic methods of AmpC detection in *Pseudomonas aeruginosa* from various clinical isolates in a tertiary care teaching hospital. *Muller J Med Sci Res* 2016;7(1):35-9.
- [3] Tam VH, Schilling AN, LaRocco MT, et al. Prevalence of AmpC over-expression in bloodstream isolates of *Pseudomonas aeruginosa*. *Clin Microbiol Infect* 2007;13(4):413-8.
- [4] Li Y, Li Q, Du Y, et al. Prevalence of Plasmid-Mediated AmpC  $\beta$ -Lactamases in a Chinese University Hospital from 2003 to 2005: First Report of CMY-2-Type AmpC  $\beta$ -Lactamase Resistance in China. *J Clin Microbiol* 2008;46(4):1317-21.
- [5] Khalil MA, Ibrahim Sonbol F, Mohamed AF, Ali SS. Comparative study of virulence factors among ESbetaL-producing and nonproducing *Pseudomonas aeruginosa* clinical isolates. *Turk J Med Sci* 2015;45(1):60-9.
- [6] El-Shaer S, Shaaban M, Barwa R, Hassan R. Control of quorum sensing and virulence factors of *Pseudomonas aeruginosa* using phenylalanine arginyl beta-naphthylamide. *J Med Microbiol* 2016;65(10):1194-204.
- [7] Schroeder M, Brooks BD, Brooks AE. The Complex Relationship between Virulence and Antibiotic Resistance. *Genes* 2017;8:39.
- [8] Tahmasebi H, Yousef Alikhani M, Dehbashi S, Arabestani MR. Investigation of the relationship between the presence of chromosomal and plasmid-encoded AmpC genes and type of clinical specimen in *pseudomonas aeruginosa*. *J Babol Univ Med Sci* 2018;20(3):36-43.
- [9] Performance standards for antimicrobial susceptibility testing; twenty-fourth Informational Supplement M100-S24. Wayne (PA): CLSI; 2014.
- [10] Mlynarcik P, Roderova M, Kolar M. Primer Evaluation for PCR and its Application for Detection of Carbapenemases in Enterobacteriaceae. *Jundishapur J Microbiol* 2016;9(1):e 29314.
- [11] Fazeli N, Momtaz H. Virulence Gene Profiles of Multidrug-Resistant *Pseudomonas aeruginosa* Isolated From Iranian Hospital Infections. *Iranian Red Crescent Med J* 2014;16(10):e15722.
- [12] Pereira SG, Rosa AC, Ferreira AS, et al. Virulence factors and infection ability of *Pseudomonas aeruginosa* isolates from a hydropathic facility and respiratory infections. *J Applied Microbiol* 2014;116 (5):1359-68.
- [13] Oglesby-Sherrouse AG, Djapgne L, Nguyen AT, Vasil AI, Vasil ML. The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of *Pseudomonas aeruginosa*. *Pathog Dis* 2014;70(3):307-20.
- [14] Toder DS, Ferrell SJ, Nezezon JL, Rust L, Iglewski BH. *lasA* and *lasB* genes of *Pseudomonas aeruginosa*: analysis of transcription and gene product activity. *Infect Immun* 1994;62(4):1320-7.
- [15] Tomaras AP, Crandon JL, McPherson CJ, et al. Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2013;57(9):4197-207.
- [16] Bonaventura G, Picciani C, Spedicato I, Piccolomini R. E-test method for detecting antibiotic synergy against *Pseudomonas aeruginosa* from neutropenic patients: A cost-effective approach. 2004. p. 263-72.
- [17] Ullah A, Javeid I, Khalid K, Hanif M, Sahrish J. In-vitro comparative Study Of Cefoperazone, Ceftazidime, Ceftizoxime, Cefotaxime, Ceftriaxone And Cefixime Against *Pseudomonas Aeruginosa*. *Int Res J Pharm* 2013;4(1):135-7.
- [18] Chen H, Wang Z, Li H, et al. In Vitro Analysis of Activities of 16 Antimicrobial Agents against Gram-Negative Bacteria from Six Teaching Hospitals in China. *Japanese J Infect Dis* 2015;68(4):263-7.
- [19] Saeed HA, Awad AA. Susceptibility of *pseudomonas aeruginosa* to third generation cephalosporins. *J Sci Tech* 2009;10(2):195-200.
- [20] Parkins MD, Pitout JD, Church DL, Conly JM, Laupland KB. Treatment of infections caused by metallo-beta-lactamase-producing *Pseudomonas aeruginosa* in the Calgary Health Region. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Eur J Clin Microbiol Infect Dis* 2007;13(2):199-202.
- [21] Yusuf E, Van Herendael B, Verbrugghe W, et al. Emergence of antimicrobial resistance to *Pseudomonas aeruginosa* in the intensive care unit: association with the duration of antibiotic exposure and mode of administration. *Ann Intensive Care* 2017;7(1):72.
- [22] Nilsson O, Borjesson S, Landen A, Bengtsson B. Vertical transmission of *Escherichia coli* carrying plasmid-mediated AmpC (pAmpC) through the



- broiler production pyramid. *J Antimicrob Chemother* 2014;69(6):1497-500.
- [23] Yan JJ, Tsai SH, Chuang CL, Wu JJ. OXA-type beta-lactamases among extended-spectrum cephalosporin-resistant *Pseudomonas aeruginosa* isolates in a university hospital in southern Taiwan. *J Microbiol J Immunol Infec* 2006;39(2):130-4.
- [24] Liu C-P, Chen T-L, Wang N-Y, Chow S-F, Lin J-C, Yan T-R. Detection of *Pseudomonas aeruginosa* isolates carrying the blaOXA-142 extended-spectrum  $\beta$ -lactamase gene in Taiwan. *J Microbiol J Immunol Infec* 2017;50(1):68-74.
- [25] Laudy AE, Rog P, Smolinska-Krol K, et al. Prevalence of ESBL-producing *Pseudomonas aeruginosa* isolates in Warsaw, Poland, detected by various phenotypic and genotypic methods. *PloS one* 2017;12(6):e0180121.
- [26] Ullah W, Qasim M, Rahman H, et al. CTX-M-15 and OXA-10 beta lactamases in multi drug resistant *Pseudomonas aeruginosa*: First report from Pakistan. *Microb Pathog* 2017;105:240-4.
- [27] Rafiee R, Eftekhari F, Tabatabaei SA, Minaee Tehrani D. Prevalence of Extended-Spectrum and Metallo  $\beta$ -Lactamase Production in AmpC  $\beta$ -Lactamase Producing *Pseudomonas aeruginosa* Isolates From Burns. *Jundishapur J Microbiol* 2014;7(9):e16436.
- [28] Geyer CN, Hanson ND. Multiplex high-resolution melting analysis as a diagnostic tool for detection of plasmid-mediated AmpC beta-lactamase genes. *J Clin Microbiol* 2014;52(4):1262-5.
- [29] Logan LK, Renschler JP, Gandra S, et al. Carbapenem-Resistant Enterobacteriaceae in Children, United States, 1999–2012. *Emerg Infect Dis* 2015;21(11):2014-21.
- [30] Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis* 2008;8(3):159-66.
- [31] Heydari S, Eftekhari F. Biofilm Formation and  $\beta$ -Lactamase Production in Burn Isolates of *Pseudomonas aeruginosa*. *Jundishapur J Microbiol* 2015;8(3):e15514.
- [32] Turk M. Carbapenem resistant *pseudomonas aeruginosa*: oprd downregulation and the types of metallo- $\beta$ -lactamases produced. University of Balamand; 2011. p. 56-62.
- [33] Ellappan K, Belgode Narasimha H, Kumar S. Coexistence of multidrug resistance mechanisms and virulence genes in carbapenem-resistant *Pseudomonas aeruginosa* strains from a tertiary care hospital in South India. *J Glob Antimicrob Resist* 2018;12:37-43.
- [34] Cornut PL, Thuret G, Creuzot-Garcher C, et al. Relationship between baseline clinical data and microbiologic spectrum in 100 patients with acute postcataract endophthalmitis. *Retina* 2012;32(3):549-57.